The patient impact of cell therapies is expected to continue to grow as therapies stretch into earlier lines of treatment in cancer and expand into new therapeutic areas, such as diabetes.
According to McKinsey analysis of data from Evaluate Pharma, cell therapies brought in more than $3 billion in sales in 2022, supported by indication expansion of chimeric antigen receptor (CAR) T-cell therapies within hematological malignancies (that is, approval in multiple myeloma and second-line large B-cell lymphoma). Sales are projected to rise to more than $21 billion by 2026, supported not only by CAR T but also by various stem-cell and immune-cell therapies expected to come to market in the coming years. The patient impact of cell therapies is expected to continue to grow as therapies stretch into earlier lines of treatment in cancer and expand into new therapeutic areas, such as diabetes.